JAZZ News and Press, Jazz Pharmaceuticals plc From 07/22/20

Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav contains 92 percent less sodium per nightly dose than sodium oxybate, a current standard of care for this patie...

DUBLIN , July 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020 , after the close of the financial markets.  Company management will host a live audio webcast imme...

Last week, we provided a ' deep dive ' on Jazz Pharmaceuticals ( JAZZ ). After the research, we passed on making any investment recommendation on the mid-cap biopharma. In part, this was because there was a potentially better candidate in the pipeline of a much smaller biopharma that could b...

DUBLIN , July 13, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Zepzelca ™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN ® ) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) fo...

Fate is just another word for people's choices coming to a head. Destiny, coincidence, whatever you name it. It inevitably lies in our hands ." - Tiffanie DeBartolo It has been quite a while since we looked at this mid-cap biopharma below. The shares have seen better days, but there are s...

Investment Thesis Jazz Pharmaceuticals 5-year share price performance. Source: TradingView . As we can see above Jazz Pharmaceuticals' ( JAZZ ) stock is trading some way below its starting 2020 starting price of $152, even further below the $178 the stock traded at in mid-2018, and near...

With the highly volatile markets fueled by rising algorithmic and day trading, it is increasingly common to see wide swings in stocks, particularly in the biotech sector. Therefore, one must be prepared to have the courage of one's convictions and accumulate fundamentally strong stocks on dips...

Jazz Pharmaceuticals (NASDAQ: JAZZ) struggled to start the year, but in the last three months, the stock is up 18.56%. The company, founded in 2003, has grown into a company with more than $2.1 billion in annual revenue and is in the process of building a huge pipeline. Here are three re...

DUBLIN , June 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced along with its partner PharmaMar (MSE: PHM) that the U.S. Food and Drug Administration (FDA) approved Zepzelca ™  (lurbinectedin) for the treatment of adult patients with m...

DUBLIN , June 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 2.000% exchangeable senior notes due 2026 in a private offering (the "offering") by Jazz Investments I Limited...